Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase which is highly homologous to angiotensin-converting enzyme (ACE). ACE2 produces vasodilator peptides angiotensin 1-7 from angiotensin II. In the present study, we synthesized various internally quenched fluorogenic (IQF) substrates (fluorophore-Xaa-Pro-quencher) based on the cleavage site of angiotensin II introducing N-terminal fluorophore N-methylanthranilic acid (Nma) and C-terminal quencher N ε -2,4-dinitrophenyl-lysine [Lys(Dnp)]. The synthesized mixed substrates "Nma-Xaa-Pro-Lys(Dnp)" were hydrolyzed by recombinant human (rh) ACE2. The amount of each product was determined by liquid chromatography mass spectrometry (LC-MS) with fluorescence detection and it was found that Nma-His-Pro-Lys(Dnp) is the most suitable substrate for rhACE2. The K m , k cat , and k cat /K m values of Nma-His-Pro-Lys(Dnp) on rhACE2 were determined to be 23.3 μM, 167 s −1 , and 7.17 μM −1 s −1 , respectively. Using the rhACE2 and the newly developed IQF substrate, we found rhACE2 inhibitory activity in soybean and isolated the active compound soybean ACE2 inhibitor (ACE2iSB). The physicochemical data on the isolated ACE2iSB were identical to those of nicotianamine. ACE2iSB strongly inhibited rhACE2 activity with an IC 50 value of 84 nM. This is the first demonstration of an ACE2 inhibitor from foodstuffs.
The renin-angiotensin system (RAS) is one of the most important blood pressure control system in mammals. Renin catalyzes the liberation of inactive decapeptide angiotensin I from its plasma substrate angiotensinogen. The produced angiotensin I is activated by angiotensin-converting enzyme (ACE). ACE is a membrane-bound and zinc-and chloridedependent peptidyl dipeptidase that cleaves C-terminus dipeptide from angiotensin I to produce active octapeptide angiotensin II. Angiotensin II is the major vasoactive peptide in the RAS, acting as a potent vasoconstrictor through its receptor AT1R (1, 14, 15) . Angiotensin II also activates the release of aldosterone from the adrenal cortex. This also causes high blood pressure. Thus, control of RAS is the major target for cardiovascular disease therapies. In 2000, human homologue of ACE, referred to as "ACE2", was identified and showed to be an essential regulator of cardiac function (4, 19) . ACE2 consists of 805 amino acids and is a type I transmembrane glycoprotein with a single extracellular catalytic motif, His-Glu-Met-Gly-His. The expression of ACE2 mRNA in human is highly restricted to the heart, kidney, and testis (4, 19) . ACE2 is a carboxypeptidase that catalyzes liberation of vasodilator peptide, angiotensin 1-7, from angiotensin II (Fig. 1) . Thus, ACE2 is responsible for counterbalancing the potent vasoconstrictor effects of angiotensin II (23) . On the other hand, ACE2 has been demonstrated to be a functional receptor for the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS) (12, 13, 21) . Moreover, ACE2
tested Nma-Phe-His-Lys(Dnp) for the determination of rhACE2 activity. However Nma-Phe-His-Lys(Dnp) was poor substrate for rhACE2 (data not shown). Thus, in the present study, we designed novel IQF substrates for rhACE2 based on the amino acid sequence of angiotensin II because angiotensin II is more susceptible than angiotensin I by rhACE2 hydrolysis (19) (Fig. 1) . Initially, we prepared mixed substrates "Nma-Xaa-Pro-Lys(Dnp)" containing 19 kinds of naturally occurring amino acids except for Cys at P 2 position (Xaa). Substrates were divided into two groups (A and B groups) because Leu and Ile have the same molecular weight and cannot be distinguished by liquid chromatography mass spectrometry (LC-MS). Group A substrates contains Ile or 9 amino acids (Ala, Pro, Gln, Asp, Thr, Met, Phe, Arg, His). Group B substrates contains Leu or 9 amino acids (Gly, Val, Asn, Glu, Ser, Trp, Tyr, Lys, His). Both groups contain Nma-His-Pro-Lys(Dnp) as an internal standard. Hydrolysis of substrates by rhACE2 was as follows. The reaction mixture contained 450 μL of 0.1 M HEPES, pH 7.5, 0.3 M NaCl, 50 μg mixed substrates, 0.01% Triton X-100, 0.02% NaN 3 , 50 μL of rhACE2 solution (50 ng/mL) in a total volume of 500 μL. The reaction mixtures were incubated at 37°C for 0-120 min. After the incubation, reactions were terminated by heating (100°C for 5 min), and then the amounts of fluorescence products (Nma-Xaa-Pro) and residual substrates (data not shown) were determined by LC-MS with fluorescence detection according to the previous report (18) . Production of Nma-Xaa-Pro from both group A and B substrates was shown in Fig. 2 . The fluorescence intensity of the products was normalized to the internal standard, Nma-His-Pro-Lys(Dnp). At 30 min point, the order of production in the group-A substrates was Nma-His-Pro (100%), Nma-Met-Pro (56.1%), Nma-Arg-Pro (52.9%), Nma-Phe-Pro (41.9%), Nma-Gln-Pro (27.1%), and Nma-Ala-Pro (8.45%). The production of Nma-Asp-Pro, Nma-Thrhas been shown to be essential for SARS-CoV infection in vitro (10) . Recently, Hashimoto et al. (5) identified that ACE2 is a key regulator of dietary amino acid homeostasis in colitis. As mentioned above, ACE2 has various physiological functions. Thus, ACE2-specific substrates and inhibitors should provide more information about the physiological roles of ACE2.
In the present study, we developed novel internally quenched fluorogenic (IQF) substrate for ACE2, Nma-His-Pro-Lys(Dnp). Using Nma-His-ProLys(Dnp) and ACE2, we screened ACE2 inhibitory activity in various foodstuffs, found that soybean contained strong ACE2 inhibitory activity, and isolated the active compound "soybean ACE2 inhibitor" (ACE2iSB). The isolated ACE2iSB was suggested to be identical to nicotianamine by direct comparison with standard compound. The recombinant human (rh) ACE2 and rhACE were obtained from Calbiochem (San Diego CA, USA; Lot: D00130319) and R&D Systems (Minneapolis, MN, USA; Lot: FQJ0207011), respectively. Authentic nicotianamine was from Santa Cruz Biotechnology (Dallas, TX, USA; Lot: D0314). Bio-gel P-4 and Sephadex G-15 were obtained from BioRad Laboratories, Inc. (Hercules, CA, USA), and GE Healthcare (Buckinghamshire, UK), respectively. The K m and k cat values were determined using Lineweaver-Burk plots. Nma-His-Pro-Lys(Dnp) and group-A and B substrates (described below) were synthesized by the solid phase method with an ABI 430A peptide synthesizer using the Boc strategy. The protected peptide resins were treated with hydrogen fluoride to give crude products, which were subsequently purified by HPLC. ACE2 inhibition assays using IQF substrates were as follows. The reaction mixture contained 40 μL of 0.1 M HEPES, pH 7.5, 0.3 M NaCl, 20 μM IQF substrate, 0.01% Trion X-100, 0.02% NaN 3 , 5 μL of inhibitor solution or buffer, and 5 μL of rhACE2 solution (50 ng/ mL) in a total volume of 50 μL. The reaction mixture was incubated at 37°C for 30 min and then the reaction was terminated by adding 0.2 mL of 0.1 M sodium borate buffer, pH 10.5. The increase in fluorescence intensity was measured at an emission wavelength at 440 nm upon excitation at 340 nm. The concentration of the inhibitor that is required for 50% inhibition of the rhACE2 activity was defined as the IC 50 value. Previously, we developed sensitive IQF substrate for rhACE based on the amino acid sequence of angiotensin I, Nma-Phe-His-Lys(Dnp) (17) . As ACE2 converts angiotensin I to angiotensin 1-9 (4), we The effects of pH and NaCl concentration on rhACE2 activity were also determined using NmaHis-Pro-Lys(Dnp). The rhACE2 activity had strong pH dependence, especially under acidic conditions. The enzyme had only 15% activity at pH 6.0 to that at optimal pH (pH 7.5). On the other hand, rhACE2 maintained substantial activity within the range of pH 7.0-pH 8.5 (Fig. 3A) . The rhACE2 activity was enhanced by the addition of NaCl. The hydrolytic activity was optimal in the presence of 0.25 M-0.5 M NaCl (Fig. 3B) . We also determined the kinetic parameters of rhACE2 for IQF substrate. The reaction mixture contained 45 μL of 0.1 M HEPES, pH 7.5, containing 0.3 M NaCl, 5-80 μM Nma-His-Pro-Lys(Dnp), 0.01% Pro, Nma-Ile-Pro, and Nma-Pro-Pro could not be detected ( Fig. 2A) . In the case of group B substrates, the order of production was Nma-His-Pro (100%), Nma-Asn-Pro (51.7%), Nma-Tyr-Pro (43.5%), NmaLys-Pro (26.7%), Nma-Trp-Pro (23.8%), Nma-LeuPro(19.0%), and Nma-Ser-Pro (5.0%). Production of Nma-Glu-Pro, Nma-Val-Pro, and Nma-Gly-Pro could not be detected (Fig. 2B) . Moreover, the amount of residual substrate, Nma-His-Pro-Lys(Dnp) was much less than those other Nma-Xaa-Pro-Lys(Dnp) substrates (data not shown). These results clearly indicate that Nma-His-Pro-Lys(Dnp) is the most suitable substrate for rhACE2. inhibitory activity were pooled and lyophilized. The lyophilized matter (9.0 mg) was used in the identification of ACE2iSB. The isolated ACE2iSB gave a protonated ion peak, (M+H) + = 304.1 by electron spray ionization mass spectrometry (ESI-MS), which was identical to the theoretical value of nicotianamine. Additionally, 1 H-NMR spectrum, HPLC retention times on octa decyl silyl (ODS) and TSKgel amide-80 (Tosoh, Tokyo), and amino acid analysis on cation-exchange columns of the isolated ACE2iSB were all identical to those of the authentic nicotianamine (Fig. 4) . Nicotianamine is a major ACE inhibitory compound in soy sauce (9) and vegetables (6, 11) . It is an intermediate compound in biosynthetic pathway of mugineic acids and ubiquitous in higher plant (16) . However, because of the delay of development of a rhACE2 assay method, the screening of rhACE2 inhibitory activity of nicotianamine has not been studied. The present results clearly indicate that nicotianamine is the rhACE2 inhibitory compound in soybean. , respectively. In previous studies, caspase-1 substrate, (7-methoxycumarin-4-yl) acetyl (MCA)-Tyr-Val-Ala-Asp-Pro-Lys(Dnp) or MCA-Ala-Pro-Lys(Dnp), was used for rhACE2 assay (7, 20, 22) , the latter being a better substrate than the former. , respectively (20) . The calculated k cat /K m value for Nma-His-ProLys(Dnp) was one order magnitude higher than that for MCA-Ala-Pro-Lys(Dnp) (20) . These results clearly indicate that newly developed Nma-His-ProLys(Dnp) is an excellent substrate for rhACE2. Using rhACE2 and the IQF substrate, we screened various foodstuffs and found that soybean contains strong rhACE2 inhibitory activity. Then, we isolated the active compound "soybean rhACE2 inhibitor" (ACE2iSB). Soybean (100 g) was soaked 1.5 L of distilled water at room temperature overnight, and heated at 105°C for 30 min. The sample was homogenized in food processor and centrifuged at 10,000 × g for 30 min. The supernatant (200 mL) was applied to a Sep-Pak Vac C18 35cc (Waters, Bedford, MA) that had been equilibrated with distilled water. The column was washed with 100 mL of distilled water. This step was repeated several times. Then the flow-through fractions were pooled and lyophilized. The lyophilized sample (9.45 g) was dissolved in 60 mL of 10% ethanol and applied to a Bio-Gel P-4 (5.5 × 65 cm) column equilibrated with 10% ethanol. The column was eluted with 10% ethanol, and fractions containing rhACE2 inhibitory activity were pooled and lyophilized. The lyophilized sample (250 mg) was dissolved in 20 mL of 10% ethanol and applied to a Sephadex G-15 (5.5 × 65 cm) column equilibrated with 10% ethanol. The column was eluted with 10% ethanol, and fractions exhibiting rhACE2 inhibitory activity were pooled and lyophilized. The lyophilized sample (64.8 mg) was dissolved in 5 mL of 10% ethanol containing 10 mg/mL of NaCl and applied to a BioGel P-4 (2.5 × 90 cm) column equilibrated with 10% ethanol. Fractions of 4 mL each were collected and monitored at 210 nm. Fractions exhibiting rhACE2 and rhACE by ACE2iSB and nicotianamine. ACE2iSB inhibited both rhACE2 and rhACE with IC 50 values of 84 nM and 62 nM, respectively (Fig. 5A) . The authentic nicotianamine also inhibited rhACE2 and rhACE with IC 50 values of 76 nM and 59 nM, respectively (Fig. 5B) . The IC 50 values of ACE2iSB and nicotianamine for rhACE2 and rhACE were indistinguishable. These results also support the assertion that ACE2iSB is nicotianamine. Recently, various peptide and synthetic ACE2 inhibitors have been developed (2, 3, 7, 8) . The ACE2 inhibitor N-(2-aminoethyl)-1-aziridine-ethanamine discovered by structure-based studies is effective in blocking the SARS coronavirus spike protein-mediated cell fusion (2) . On the other hand, synthetic ACE2 inhibitor, GL1001 has anti-inflammatory activity in the mouse digestive tract (3). The isolated novel rhACE2 inhibitor from soybean, nicotianamine, is a beneficial compound for in vivo studies because of its origin in a foodstuff. Nicotianamine should be a useful tool for elucidation of physiological function of ACE2. Detailed inhibition kinetic studies of nicotianamine on ACE2 are underway.
